Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Thyroid Nodule 1Social Isolation 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurobehavioral Manifestations 1Lung Neoplasms 1Disease 1Depression 1Communication 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Artificial Intelligence × Clear all
NCT04340180 2026-01-22

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

University of Alabama at Birmingham

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡